Developing first-in-class therapeutics based on cutting-edge science:

ExomeresTM by Exopharm.

 

Therapeutic ExomeresTM

from Stem Cells

Exomeres are biological nanoparticles naturally secreted by stem cells. They are produced using Exopharm’s proprietary LEAP process, which delivers a unique blend of exosomes / vesicles with high-yield.


Exomeres are a cell-free super-drug with the potential to treat a range of conditions such as osteoarthritis, eye disease and fibrosis as a regenerative medicine.


Exomeres carry a rich molecular cargo of nucleic acids, lipids and proteins and are taken up by cells inside the body.


Harnessing natural mechanisms, Exomeres transfer information, energy and cell building materials between cells that promote tissue repair, healing and regeneration

Advancing knowledge in stem-cell therapy is demonstrating that positive medical outcomes can be achieved even without using the therapeutic cells themselves. Instead, the essential therapeutic components are the cell-secreted extracellular vesicles (EVs), including exosomes.


It has become apparent that these EVs alone are sufficient to deliver beneficial effects in models of disease – by efficient delivery of the information, machinery and energy to drive repair programs in damaged tissues. While delivering the therapeutic benefits, Exomeres offer a range of advantages over the use of cells for therapy. Being cell-free, they are easy to transport and deliver to patients around the world. Exomeres also cause less concern over their safety as they are not living cells: they have much more pharmaceutical properties and will not remain in the body for extended periods.


Exomeres – a completely new class of biological therapeutic.

Exopharm is investing in the pharma-grade manufacturing process and preclinical development of Exomeres to enable first clinical trials for the treatment of joint conditions, eye disease and fibrosis.

News

Exopharm Q&A with Jason Howitt, neurobiologist at Swinburne University of Technology and the Florey Institute of Neuroscience and Mental Health in Melbourne

Exosomes could be critical players in the onset of Parkinson’s and other neurodegenerative disorders, says Jason Howitt What’s the focus of your research? For our exosome research, the main focus is Parkinson’s disease and related neurodegenerative disorders. Parkinson’s disease is associated with the formation in the brain of misfolded clumps of a protein called α-synuclein. We’ve found a way that α-synuclein is packaged inside exosomes, and we’ve been studying how that can affect the brain to cause the disease. The other focus we have is how exosomes work in the body in general – how they move in the body, where they can move to, and what they do. As a neurobiologist, what first...
Read More

Exosomes linking obesity and diabetes

Exosomes from lean individuals can reverse the symptoms of diabetes associated with obesity, a new animal study shows Inflammatory exosomes are the missing link by which obesity causes type 2 diabetes, researchers from the University of California San Diego have shown. The discovery could lead to earlier diabetes diagnosis and new ways to treat the disease, the researchers say. Overweight or obese individuals have a heightened risk for several health conditions, including type 2 diabetes. In fact, obesity is the most common cause of the disease. Patients with diabetes are insulin resistant, which means their body can no longer keep its blood glucose levels in check. As a result,...
Read More

Exosomes: An investor’s guide

Investors in biotechnology are like two-headed beings – interested in exceptional financial returns, as well as in ground-breaking innovations that will improve the health of their loved ones. The Nasdaq Biotech Index has grown 145% over the past 5 years, compared with 116% for the Nasdaq Composite Index and 78% for the S&P 500 over the same period [1]. And activity in the biotech area is still picking up. In October 2017, US biopharma giant Gilead acquired Nasdaq listed biotech company Kite Pharma for US$11.9 billion [2]. Kite was formed in 2009 and is reported to have raised around US$800 million since 2011. Kite’s (now Gilead’s) product is a yet-to-be-approved therapy that takes...
Read More

Our Team.

Dr. Ian Dixon

CEO

linkedin

Dr. Gregor Lichtfuss

COO

twitter linkedin

Dr. Jim Palmer

Drug Development

linkedin

Melbourne - Australia